2. Search Result
Search Result
Results for "

plasma concentrations

" in MedChemExpress (MCE) Product Catalog:

105

Inhibitors & Agonists

4

Fluorescent Dyes

7

Biochemical Assay Reagents

4

Peptides

1

Inhibitory Antibodies

16

Natural
Products

5

Isotope-Labeled Compounds

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W018781
    Benzamidine hydrochloride
    3 Publications Verification

    		 Ser/Thr Protease Cancer
    Benzamidine hydrochloride is a competitive protease inhibitor that blocks the hydrolytic cleavage of glucagon by plasmin, trypsin and thrombin. Benzamidine hydrochloride effectively inhibits the degradation of glucagon by relevant proteases during the collection, storage and analysis of human plasma and blood samples. During in vivo metabolism, Benzamidine hydrochloride undergoes N-hydroxylation and produces multiple metabolites, exhibiting characteristics of delayed excretion or biphasic elimination. Benzamidine hydrochloride only induces slight single-strand DNA breaks at high concentrations and shows no significant genotoxic potential overall. Benzamidine hydrochloride may interfere with the detection of some glucagon antisera, but does not affect key antigen-antibody affinity at specific concentrations. Benzamidine hydrochloride can be used as a stabilizer in glucagon radioimmunoassays to ensure the accuracy and recovery rate of detection results .
    Benzamidine hydrochloride
  • HY-12594
    Paritaprevir
    Maximum Cited Publications
    13 Publications Verification

    ABT-450; Veruprevir

    		 HCV Protease HCV SARS-CoV Infection
    Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor) .
    Paritaprevir
  • HY-17383
    Levomefolate calcium
    3 Publications Verification

    		 Antifolate Cardiovascular Disease Neurological Disease
    Levomefolate calcium is a synthetic calcium salt of L-5-methyltetrahydrofolate and an orally active and brain-penetrant folate supplement. Levomefolate calcium incorporates into body folate pools to increase plasma and red blood cell folate levels over time. Levomefolate calcium does not significantly increase folate concentrations in breast milk. Levomefolate calcium can be used for the research of neural tube defects and megaloblastic anemia .
    Levomefolate calcium
  • HY-B2209
    Hydroxocobalamin
    3 Publications Verification

    Vitamin B12a

    		 Endogenous Metabolite Neurological Disease Metabolic Disease
    Hydroxocobalamin (Vitamin B12a) is a cyanide antidote. Hydroxocobalamin can decrease the cell and plasma cyanide concentrations and increase survival rate in acute cyanide poisoning. Hydroxocobalamin can improve newborn Cbl-C defect-induced metabolic profile and neurocognitive outcome. Hydroxocobalamin can normalize Vitamin B12 deficiency. Hydroxocobalamin can induce acute kidney injury. Hydroxocobalamin can be used for the researches of metabolic and neurological disease .
    Hydroxocobalamin
  • HY-W008491
    TK-112690

    		Phosphorylase Inflammation/Immunology Cancer
    TK-112690 is a UPP1 inhibitor. TK-112690 inhibits murine small intestinal uridine phosphorylase (UPase) with an IC50 of 12.5 μM and human small intestinal UPase with an IC50 of 20.0 μM in vitro. TK-112690 increases plasma uridine concentration in mice. TK-112690 can be used for the study of cancer and pulmonary fibrosis .
    TK-112690
  • HY-113166
    Dodecanoylcarnitine
    1 Publications Verification

    (-)-Lauroylcarnitine

    		 Endogenous Metabolite Metabolic Disease Inflammation/Immunology
    Dodecanoylcarnitine ((-)-Lauroylcarnitine) is a medium long-chain acylcarnitine, an intermediate product in key energy metabolic pathways of fatty acid β-oxidation and amino acids catabolism. The abnormal decrease in the Dodecanoylcarnitine levels indicats that mitochondrial fuel metabolism, including fatty acid oxidation is significantly disturbed. Changes in plasma concentrations of Dodecanoylcarnitine are not only associated with type II diabetes, but also with pre-diabetes status. Dodecanoylcarnitine is present in fatty acid oxidation disorders such as long-chain acyl CoA dehydrogenase deficiency, carnitine palmitoyltransferase I/II deficiency, and is also associated with celiac disease. Dodecanoylcarnitine deomonstrates high sensitivities and specificities in predicting asthma. Combined model of Decanoylcarnitine (HY-113069), Dodecanoylcarnitine, PC (16:0/0:0), and Asp Arg Pro can be used as a potential biomarker for the diagnosis of Yin-deficiency-heat syndrome .
    Dodecanoylcarnitine
  • HY-N11200
    3-Hydroxyisovalerylcarnitine

    		Endogenous Metabolite Metabolic Disease
    3-Hydroxyisovalerylcarnitine is a carnitine derivative. 3-Hydroxyisovaleryl carnitine in plasma may serve as a novel biomarker of biotin deficiency in humans, with its concentration increasing with biotin deficiency. Biotin deficiency reduces the activity of biotin-dependent 3-methylcrotonyl-CoA carboxylase, hinders the conversion of 3-methylcrotonyl-CoA into 3-methylglutaconyl-CoA, and impairs the leucine catabolism pathway; resulting in plasma 3-Hydroxyisovalerylcarnitine concentrations rise .
    3-Hydroxyisovalerylcarnitine
  • HY-70002A
    N-Desmethyl enzalutamide
    1 Publications Verification

    N-Desmethyl MDV 3100

    		 Androgen Receptor Cancer
    N-desmethyl Enzalutamide is the active metabolite of Enzalutamide.N-desmethyl Enzalutamide is the active metabolite of Enzalutamide. N-desmethyl Enzalutamide demonstrates primary and secondary pharmacodynamics of similar potency to Enzalutamide and circulates at approximately the same plasma concentrations as enzalutamide .
    N-Desmethyl enzalutamide
  • HY-126573
    Trilaurin

    		Endogenous Metabolite Biochemical Assay Reagents Cardiovascular Disease Metabolic Disease Cancer
    Trilaurin is an orally active triglyceride. Trilaurin inhibits DMBA-induced, croton oil-promoted skin tumor formation in Swiss Webster mice. Trilaurin increases plasma high-density lipoprotein cholesterol and apolipoprotein A-I concentrations. Trilaurin is used as an occlusive skin conditioning agent and/or non-aqueous thickener in cosmetics .
    Trilaurin
  • HY-DY1057
    TMA-DPH (solution)

    		Fluorescent Dye Others
    TMA-DPH (solution) is a hydrophobic fluorescent membrane probe (Ex=355 nm; Em=430 nm). TMA-DPH is able to anchor on the cell surface and localize to different regions of the phospholipid bilayer. By analyzing the fluorescence polarization values of TMA-DPH in the plasma membrane and membrane substructures, the fluidity of the cell membrane can be determined .
    Solvent and concentration: DMSO: 10 mM
    TMA-DPH (solution)
  • HY-125913
    Benzamidine
    3 Publications Verification

    		 Ser/Thr Protease Inflammation/Immunology
    Benzamidine is a competitive protease inhibitor that blocks the hydrolytic cleavage of glucagon by plasmin, trypsin and thrombin. Benzamidine effectively inhibits the degradation of glucagon by relevant proteases during the collection, storage and analysis of human plasma and blood samples. During in vivo metabolism, Benzamidine undergoes N-hydroxylation and produces multiple metabolites, exhibiting characteristics of delayed excretion or biphasic elimination. Benzamidine only induces slight single-strand DNA breaks at high concentrations and shows no significant genotoxic potential overall. Benzamidine may interfere with the detection of some glucagon antisera, but does not affect key antigen-antibody affinity at specific concentrations. Benzamidine can be used as a stabilizer in glucagon radioimmunoassays to ensure the accuracy and recovery rate of detection results .
    Benzamidine
  • HY-113493
    4-Pyridoxic acid

    		Endogenous Metabolite Metabolic Disease
    4-Pyridoxic acid is an endogenous substrate of renal organic anion transporters (OAT1/3) and a catabolite of vitamin B6. 4-Pyridoxic acid is excreted through OAT1/3-mediated tubular active secretion, which can reflect OAT1/3 activity. Elevated plasma concentrations of 4-Pyridoxic acid are associated with decreased OAT1/3 activity in chronic kidney disease (CKD) and can be used as a biomarker to reflect the severity of knee osteoarthritis (KOA) and lumbar spondylosis (LS) .
    4-Pyridoxic acid
  • HY-113152
    Hypogeic acid (50mg/ml in ethanol)

    		Endogenous Metabolite Neurological Disease Inflammation/Immunology
    Hypogeic acid is a fatty acid and endogenous metabolite, with a concentration of 50 mg/mL in ethanol. The plasma level of Hypogeic acid is negatively correlated with the prevalence of interstitial lung disease in idiopathic inflammatory myopathy. Hypogeic acid can be used in studies related to idiopathic inflammatory myopathy .
    Hypogeic acid (50mg/ml in ethanol)
  • HY-128387
    2,3-Butanediol

    		Endogenous Metabolite Cardiovascular Disease
    2,3-Butanediol is microbially derived compound that is a discriminating urinary biomarker of Fmo5 -/- mice. 2,3-Butanediol prevents age-related increases in the plasma concentration of cholesterol. 2,3-Butanediol has potential applications in the manufacture of printing inks, perfumes, fumigants, moistening and softening agents, plasticizers, and as a carrier for pharmaceuticals .
    2,3-Butanediol
  • HY-172550
    MS7710

    		HCN Channel Neurological Disease
    MS7710 is a hyperpolarization-activated cyclic nucleotide-gated (HCN) channel inhibitor with blood-brain barrier permeability and an excellent brain/plasma concentration ratio. MS7710 inhibits HCN channel-mediated Ih current, and reduces the firing frequency and burst activity of dopaminergic neurons in the ventral tegmental area. MS7710 ameliorates chronic social defeat stress-induced deficits in social interaction and impairments in reward-related cognitive flexibility in mice. MS7710 exerts only limited effects on ventral tegmental area dopaminergic neuron activity, social interaction, exploratory behavior, locomotor activity or sucrose preference in control mice. MS7710 is applicable to the research of major depressive disorder .
    MS7710
  • HY-12089
    Torcetrapib

    CP-529414

    		 CETP Endocrinology
    Torcetrapib (CP-529414) is a selective, potent cholesteryl ester transfer protein (CETP) inhibitor. A typical inhibition curve for whole human plasma, having a CETP concentration of 37 nM .
    Torcetrapib
  • HY-W087928
    Bromocresol purple

    		Biochemical Assay Reagents Others
    Bromocresol purple is a pH indicator, whose color changes from yellow to purple when the pH increases from 5.2 to 6.8. Bromocresol purple can be used for detecting yeast cells with plasma membrane damage and measuring serum albumin concentrations .
    Bromocresol purple
  • HY-P11292
    Caloxin 1b3

    		Calcium Channel Cardiovascular Disease
    Caloxin 1b3, a peptide, is a selective plasma membrane Ca 2+ pump 1 (PMCA1) inhibitor. Caloxin 1b3 significantly inhibits PMCA1 Ca 2+–Mg 2+-ATPase in the rabbit duodenal mucosa than the PMCA4 in the human erythrocyte ghosts. Caloxin 1b3 also increases cytosolic Ca 2+ concentration in endothelial cells. Caloxin 1b3 can be used for cardiovascular disorders research .
    Caloxin 1b3
  • HY-162562
    E28362

    		PCSK9 Metabolic Disease Inflammation/Immunology
    E28362 is an orally active lipid-lowering agent and a selective PCSK9 antagonist. E28362 blocks the interaction between PCSK9 and LDLR, and induces PCSK9 degradation via the ubiquitin-proteasome pathway. E28362 significantly increases the levels of cell surface and total LDLR proteins, enhances low-density lipoprotein uptake, thereby effectively reducing plasma lipids, hepatic cholesterol and triglyceride levels. E28362 shows no obvious cytotoxicity at high concentrations, and significantly attenuates atherosclerotic lesions in animal models. E28362 is an important molecule in research of hyperlipidemia and atherosclerosis .
    E28362
  • HY-DY1048
    DAF-FM DA (solution)

    		Fluorescent Dye Cancer
    DAF-FM DA (Diaminofluorescein-FM diacetate) (solution) is a fluorescent probe for the detection and bioimaging of nitric oxide (NO). DAF-FM DA spontaneously crosses the plasma membrane and is subsequently cleaved by esterases to generate intracellular DAF-FM (Ex/Em=495/515 nm) .
    Solvent and concentration: DMSO: 2 mM
    DAF-FM DA (solution)
  • HY-149120
    ASM-IN-1

    		Phospholipase Cardiovascular Disease Inflammation/Immunology
    ASM-IN-1 is a potent and orally active acid sphingomyelinase (ASM) inhibitor with an IC50 value of 1.5 µM. ASM-IN-1 reduces lipid plaques in the aortic arch and aorta and reduces plasma ceramide concentration and Ox-LDL levels. ASM-IN-1 shows antiatherosclerotic and anti-inflammatory activity .
    ASM-IN-1
  • HY-138559
    GW604714X
    1 Publications Verification

    		 Mitochondrial Metabolism Neurological Disease
    GW604714X is a potent inhibitor of mitochondrial respiration supported by pyruvate but not other substrates. GW604714X is a highly specific mitochondrial pyruvate carrier (MPC) inhibitor with a Ki <0.1 nM. GW604714X also inhibits L-lactate transport by the plasma membrane monocarboxylate transporter (MCT1), but at concentrations more than 4 orders of magnitude greater than the MPC .
    GW604714X
  • HY-14826
    Tilivapram

    AVE8112

    		 Phosphodiesterase (PDE) Neurological Disease
    Tilivapram (AVE8112) is an orally active PDE4 inhibitor with procognitive effects. Tilivapram exhibits in vivo efficacy and improves processing speed and psychomotor speed. Oral administration of tilivapram may induce dose-related adverse reactions such as nausea and dizziness, but transdermal delivery enables slow, controlled elevation of plasma concentrations, thereby significantly reducing gastrointestinal discomfort and dizziness. Tilivapram is applicable to research related to neuropsychiatric disorders .
    Tilivapram
  • HY-W019704
    N-Acetyl-DL-methionine

    		Amino Acid Derivatives Metabolic Disease
    N-Acetyl-DL-methionine is an orally active methionine analog and a glutathione (GSH) precursor that can be metabolized into cysteine in vivo. N-Acetyl-DL-methionine increases plasma methionine concentration and the molar percentage of plasma lysine in castrated sheep, and can partially meet the methionine requirement of growing rats. N-Acetyl-DL-methionine is absorbable from the lower digestive tract of sheep and undergoes ruminal microbial degradation in vivo. N-Acetyl-DL-methionine alleviates Acetaminophen (HY-66005)-induced hepatic GSH depletion in mice, maintains hepatocyte integrity, and promotes de novo synthesis of hepatic GSH. N-Acetyl-DL-methionine can be used in studies related to acetaminophen-induced liver injury .
    N-Acetyl-DL-methionine
  • HY-W014134
    p-APMSF hydrochloride

    p-Amidinophenylmethylsulfonylfluoride hydrochloride

    		 Ser/Thr Protease Inflammation/Immunology
    p-APMSF (p-Amidinophenylmethylsulfonylfluoride) hydrochloride is a serine protease and trypsin inhibitor with the characteristic of rapid onset of action. p-APMSF hydrochloride reduces the enzymatic hydrolysis of recombinant human G-CSF in rat pulmonary mucosa. Combined intratracheal treatment with p-APMSF hydrochloride and Laureth-9 significantly enhances its absorption efficiency in rat lungs. Following intranasal administration, p-APMSF hydrochloride does not increase the concentration of recombinant human G-CSF in rat plasma, nor does it alter the effect of G-CSF on inducing an increase in total white blood cell count .
    p-APMSF hydrochloride
  • HY-101005
    N-Methylhistamine dihydrochloride

    Nα-Methylhistamine dihydrochloride

    		 Histamine Receptor Sodium Channel Infection
    N-Methylhistamine dihydrochloride (Nα-Methylhistamine dihydrochloride) is a non-selective Histamine receptor agonist. N-Methylhistamine dihydrochloride activates histamine H1, H2 and H3 receptors; it stimulates central H1 receptors by activating sympathetic α and β adrenergic receptors to inhibit intestinal transit, exerts dose-dependent inhibition on intestinal transit, reduces histamine turnover in mouse brains, and increases gastric acid secretion without altering plasma gastrin concentrations. N-Methylhistamine dihydrochloride produces a pH-dependent, voltage-independent potentiating effect on acid-sensing ion channel 1a, and shows no significant activity toward homologous ASIC2a channels. N-Methylhistamine dihydrochloride can be used in studies related to Helicobacter pylori infection .
    N-Methylhistamine dihydrochloride
  • HY-101764
    Lintitript

    SR 27897

    		 Cholecystokinin Receptor Metabolic Disease
    Lintitript (SR 27897) is a highly potent, selective, orally active, competitive and non-peptide cholecystokinin (CCK1) receptor antagonist with an EC50 of 6 nM and a Ki of 0.2 nM. Lintitript displays > 33-fold selectivity more selective for CCK1 than CCK2 receptors (EC50 value of 200 nM). Lintitript increases plasma concentration of leptin and food intake as well as plasma concentration of insulin .
    Lintitript
  • HY-119393
    Olanzapine N-oxide

    		Drug Metabolite Others
    Olanzapine N-oxide is a compound under investigation for the metabolism of antipsychotic compounds. Olanzapine N-oxidation and N-demethylation are catalyzed by different enzymes, and its plasma concentration and clearance are not affected by a single factor, such as a specific genotype or smoking behavior.
    Olanzapine N-oxide
  • HY-W011180
    Vitamin A Propionate

    		Drug Derivative Others
    Vitamin A Propionate is an ester compound of vitamin A. In nutritional studies of foals, different doses have different effects on growth, serum biochemistry and hematological indicators. Too high or too low doses will produce adverse effects and are related to the vitamin A concentration in plasma, liver and kidneys.
    Vitamin A Propionate
  • HY-14196
    Toloxatone
    1 Publications Verification

    MD 69276

    		 Monoamine Oxidase Neurological Disease
    Toloxatone (MD 69276) is a reversible, selective MAO-A inhibitor that can cross the blood-brain barrier. Toloxatone increases the levels of serotonin (5-HT) and norepinephrine in the brain. Toloxatone reduces the immobility time in the forced swimming test in mice, inhibits killing behavior in rats without causing sedation, and shows a correlation between its free plasma concentration and cerebrospinal fluid concentration. Toloxatone is widely used in research related to depression, depressive disorders and Parkinson's disease .
    Toloxatone
  • HY-W087937
    Benzamidine hydrochloride hydrate
    3 Publications Verification

    Benzenecarboximidamide hydrochloride hydrate

    		 Ser/Thr Protease Cancer
    Benzamidine (Benzenecarboximidamide) hydrochloride hydrate is a competitive protease inhibitor that blocks the hydrolytic cleavage of glucagon by plasmin, trypsin and thrombin. Benzamidine hydrochloride hydrate effectively inhibits the degradation of glucagon by relevant proteases during the collection, storage and analysis of human plasma and blood samples. During in vivo metabolism, Benzamidine hydrochloride hydrate undergoes N-hydroxylation and produces multiple metabolites, exhibiting characteristics of delayed excretion or biphasic elimination. Benzamidine hydrochloride hydrate only induces slight single-strand DNA breaks at high concentrations and shows no significant genotoxic potential overall. Benzamidine hydrochloride hydrate may interfere with the detection of some glucagon antisera, but does not affect key antigen-antibody affinity at specific concentrations. Benzamidine hydrochloride hydrate can be used as a stabilizer in glucagon radioimmunoassays to ensure the accuracy and recovery rate of detection results .
    Benzamidine hydrochloride hydrate
  • HY-D1056C1
    Lipopolysaccharides, from S. enterica serotype enteritidis

    LPS, from Salmonella enterica (Serotype enteritidis)

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides, from S. enterica (Salmonella enterica) serotype enteritidis are lipopolysaccharide endotoxins and TLR-4 activators derived from the enteritidis serotype of S. enterica, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from S. enterica serotype enteritidis exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from S. enterica serotype enteritidis can induce systemic inflammatory responses, increasing levels of TNF-α, IFN-γ, IL-6, IL-10, and nitrate in plasma .
    It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
    Lipopolysaccharides, from S. enterica serotype enteritidis
  • HY-70002AS
    N-Desmethyl enzalutamide-d6

    N-Desmethyl MDV 3100-d6

    		 Androgen Receptor Cancer
    N-desmethyl Enzalutamide-d6 is a deuterium labeled N-desmethyl Enzalutamide. N-desmethyl Enzalutamide is an active metabolite of Enzalutamide. N-desmethyl Enzalutamide is the active metabolite of Enzalutamide. N-desmethyl Enzalutamide demonstrates primary and secondary pharmacodynamics of similar potency to Enzalutamide and circulates at approximately the same plasma concentrations as enzalutamide .
    N-Desmethyl enzalutamide-d6
  • HY-135730
    Aglepristone

    		Endogenous Metabolite Endocrinology
    Aglepristone is a synthetic steroidal antiprogestin with abortifacient activity. Aglepristone is used exclusively as an abortifacient in pregnant animals. Aglepristone has been shown to be a safe and effective abortifacient in the second trimester of pregnancy. Aglepristone causes termination of pregnancy and does not cause fetal resorption. During aglepristone treatment, an increase in plasma concentrations of prolactin was observed, while progesterone levels remained unchanged. The use of aglepristone also resulted in early arrest of corpus luteum function and a shortening of the estrus interval .
    Aglepristone
  • HY-128387R
    2,3-Butanediol (Standard)

    		Reference Standards Endogenous Metabolite Cardiovascular Disease
    2,3-Butanediol (Standard) is the analytical standard of 2,3-Butanediol (HY-128387). This product is intended for research and analytical applications. 2,3-Butanediol is microbially derived compound that is a discriminating urinary biomarker of Fmo5 -/- mice. 2,3-Butanediol prevents age-related increases in the plasma concentration of cholesterol. 2,3-Butanediol has potential applications in the manufacture of printing inks, perfumes, fumigants, moistening and softening agents, plasticizers, and as a carrier for pharmaceuticals.
    2,3-Butanediol (Standard)
  • HY-128387S1
    2,3-Butanediol-d8

    		Isotope-Labeled Compounds Endogenous Metabolite Cardiovascular Disease
    2,3-Butanediol-d8 is the deuterium labeled 2,3-Butanediol (HY-128387) . 2,3-Butanediol is microbially derived compound that is a discriminating urinary biomarker of Fmo5 -/- mice. 2,3-Butanediol prevents age-related increases in the plasma concentration of cholesterol. 2,3-Butanediol has potential applications in the manufacture of printing inks, perfumes, fumigants, moistening and softening agents, plasticizers, and as a carrier for pharmaceuticals .
    2,3-Butanediol-d8
  • HY-17383R
    Levomefolate calcium (Standard)

    		Reference Standards Antifolate Cardiovascular Disease Neurological Disease
    Levomefolate calcium (Standard) is the analytical standard of Levomefolate calcium. This product is intended for research and analytical applications. Levomefolate calcium is a synthetic calcium salt of L-5-methyltetrahydrofolate and an orally active and brain-penetrant folate supplement. Levomefolate calcium incorporates into body folate pools to increase plasma and red blood cell folate levels over time. Levomefolate calcium does not significantly increase folate concentrations in breast milk. Levomefolate calcium can be used for the research of neural tube defects and megaloblastic anemia .
    Levomefolate calcium (Standard)
  • HY-162484
    GZNL-P36

    		SARS-CoV Virus Protease Infection
    GZNL-P36 is an orally active inhibitor for SARS-CoV-2 papain-like protease (PL pro), with an IC50 of 6.45 nM. GZNL-P36 inhibits SARS-CoV and its variants with EC50 range from 58.2 nM to 2.66 μM. GZNL-P36 exhibits a peak plasma concentration Cmax of 549 ng/mL, a half-life T1/2 of 1.45 h and a bioavailability of 74.7% in CD-1 mouse. GZNL-P36 exhibits antiviral activity in SARS-CoV-2 XXB.1 infection in mouse .
    GZNL-P36
  • HY-138011
    Dolutegravir O-β-D-glucuronide

    Dolutegravir glucuronide; DTG glucuronide

    		 Biochemical Assay Reagents Others
    Dolutegravir O-β-D-glucuronide (Dolutegravir glucuronide) is a compound used for the simultaneous determination of rilpivirine and dolutegravir concentrations in human plasma.
    Dolutegravir O-β-D-glucuronide
  • HY-129982
    SC-435

    		Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease
    SC-435 is an orally effective apical sodium codependent bile acid transporter (ASBT) inhibitor. SC-435 effectively removes neurotoxic bile acids and ammonia from the blood by inhibiting intestinal ASBT, thereby alleviating liver and brain damage caused by liver failure. SC-435 can alter hepatic cholesterol metabolism and lower plasma low-density lipoprotein-cholesterol concentrations .
    SC-435
  • HY-145486
    1-Arachidonoyl-sn-glycerol 3-phosphate ammonium

    20:4 Lyso PA

    		 Liposome Neurological Disease
    1-Arachidonoyl-sn-glycerol 3-phosphate ammonium (20:4 Lyso PA) is a phospholipid and an LPA derived from arachidonic acid. The concentration of 1-Arachidonoyl-sn-glycerol 3-phosphate ammonium in plasma is significantly correlated with the age of onset of cocaine use and the duration of abstinence. 1-Arachidonoyl-sn-glycerol 3-phosphate ammonium can be used in the research of biomarkers for cocaine use disorder (CUD) .
    1-Arachidonoyl-sn-glycerol 3-phosphate ammonium
  • HY-W754151
    N-Desmethyl apalutamide-d4

    		Isotope-Labeled Compounds Others
    N-Desmethyl apalutamide-d4 is the deuterium-labeled N-Desmethyl-Apalutamide (HY-135331). N-Desmethyl Apalutamide is an active metabolite of Apalutamide. N-Desmethyl Apalutamide is a less potent antagonist of the androgen receptor and is responsible for one-third of the activity of Apalutamide. The formation of N-Desmethyl Apalutamide mediated predominantly by CYP2C8 and CYP3A4. N-Desmethyl Apalutamide is moderate to strong CYP3A4 and CYP2B6 inducer and has an excellent plasma-proteins bound concentration .
    N-Desmethyl apalutamide-d4
  • HY-163783
    CSNK2-IN-1

    		Casein Kinase Infection
    CSNK2-IN-1 is a potent and selective CSNK2 inhibitor with IC50 of 1.7 nM and 0.66 nM for CSNK2A1 and CSNK2A2, respectively. CSNK2-IN-1 has antiviral activity against beta-coronaviruses such as SARS-CoV-2 and MHV. CSNK2-IN-1 has good solubility, metabolic stability, and low cytotoxicity, but its plasma concentration in vivo decreases rapidly and is insufficient to achieve pharmacological effects. CSNK2-IN-1 can be used in the research of antiviral drug development .
    CSNK2-IN-1
  • HY-W110790
    Bromocresol purple sodium

    		Biochemical Assay Reagents Others
    Bromocresol purple sodium is a pH indicator, whose color changes from yellow to purple when the pH increases from 5.2 to 6.8. Bromocresol purple sodium can be used for detecting yeast cells with plasma membrane damage and measuring serum albumin concentrations .
    Bromocresol purple sodium
  • HY-148247
    BI-2081

    		Free Fatty Acid Receptor Metabolic Disease
    BI-2081, a chemical probe, is a GPR40 (FFAR1) partial agonist (EC50: 4 nM). BI-2081 induces glucose depending insulin secretion and reduces the plasma glucose concentration. BI-2081 can be used in the research of metabolic diseases, in particular diabetes type 2 .
    BI-2081
  • HY-117747
    DMP 323

    JCR 424; XM 323

    		 HIV Protease Infection
    DMP 323 is a potent, nonpeptide cyclic urea inhibitor of HIV protease, effective against both HIV type 1 and type 2. Designed using structural information and database searching, it competitively inhibits the cleavage of both peptide and HIV-1 gag polyprotein substrates. DMP 323 shows comparable potency to other highly effective HIV protease inhibitors like A-80987 and Ro-31-8959. Importantly, its efficacy against HIV protease remains unaffected by human plasma or serum, suggesting low affinity for plasma proteins. Furthermore, DMP 323 demonstrates minimal inhibition of various mammalian proteases at concentrations much higher than those needed for HIV protease inhibition, highlighting its specificity for viral targets .
    DMP 323
  • HY-33914
    4-Hydroxymethylpyrazole

    		Drug Metabolite Metabolic Disease
    4-Hydroxymethylpyrazole is the primary metabolite of Fomepizole (HY-B0876) produced through hepatic oxidative metabolism. 4-Hydroxymethylpyrazole exhibits a plasma concentration that is positively correlated with the administered dosage of Fomepizole, and it demonstrates a relatively short half-life. 4-Hydroxymethylpyrazole demonstrates inhibitory effects on alcohol dehydrogenase (ADH) in both humans and monkeys, but its inhibition constant is significantly higher than that of Fomepizole, rendering its in vivo impact negligible .
    4-Hydroxymethylpyrazole
  • HY-19106
    MCI-727 free base

    		Secretin Receptor Inflammation/Immunology Endocrinology
    MCI-727 free base is an orally active anti-ulcer agent. MCI-727 free base can increase the plasma secretin concentration in rats and dogs. MCI-727 free base can also stimulate the exocrine function of the pancreas in rats by promoting the release of endogenous secretin, and exert preventive and therapeutic effects on mild acute pancreatitis. MCI-727 free base can be used in the research of ulcer-related diseases .
    MCI-727 free base
  • HY-W127408
    Tripalmitolein

    		Biochemical Assay Reagents Endogenous Metabolite Others
    1,2,3-Tripalmitoleoyl-rac-glycerol is a triacylglycerol containing palmitoleic acid at the sn-1, sn-2 and sn-3 positions. It reduces erythrocyte deformability in a concentration-dependent manner in the Reid filtration assay. Hepatic levels of 1,2,3-tripalmitoleoyl-rac-glycerol are increased in a JAK2L mouse model of hepatic steatosis. 1,2,3-Tripalmitoleoyl-rac-glycerol plasma levels are reduced in patients with predialysis renal disease.
    Tripalmitolein
  • HY-117913
    ES-8891

    		Renin Cardiovascular Disease
    ES-8891 is a renin inhibitor. Oral administration of ES-8891 to normotensive sodium-depleted macaques for one week significantly reduced plasma renin activity, immunoreactive renin concentrations, and plasma angiotensin I concentrations, while mean blood pressure decreased significantly, without significant changes in heart rate. ES-8891 regulates blood pressure by inhibiting plasma renin levels and renal renin synthesis .
    ES-8891

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: